JAAD international · 2025
Antidesmoglein 1 and 3 serum IgG and positivity by direct immunofluorescence microscopy is associated with relapse in pemphigus in a prospective bicontinental study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
De Dipankar, Shilpa Shipla, Kumar Sheetanshu, Drenovska Kossara, Mehta Hitaishi, van Beek Nina, Sachdeva Naresh, Fleva Alexandra, Shahid Martin, Handa Sanjeev, Giannakou Anastasia, Naumova Elissaveta, Mahajan Rahul, Kyriakou Aikaterini, Lesichkova Spaska, Lazaridou Elisabeth, Radotra Bishan Dass, Kishore Kamal, Vassileva Snejina, Patsatsi Aikaterini, Schmidt Enno
Аннотация
BACKGROUND: Prospective studies identifying immunological parameters that can predict clinical relapse in pemphigus are scarce.
OBJECTIVE: To periodically assess immunological parameters in patients with pemphigus vulgaris and foliaceous in remission to understand immunological events preceding clinical relapse.
METHODS: A total of 105 patients were included. Baseline assessment included direct immunofluorescence (DIF), serum IgG against desmoglein (Dsg) 1, IgG, IgG1, and IgG4 against Dsg 3, IgG against the extracellular domains 1 and 2 of Dsg 3, IgG against muscarinic (M3)-AchR, and peripheral CD19+CD27+ memory B cells/plasma cells, repeated every 3 months for up to 12 months or until clinical relapse. DIF was repeated at month 12 and on relapse.
RESULTS: About 29 of 105 patients (28%) experienced a relapse. Longer duration of clinical remission, presence of pruritus and positive anti-Dsg1 at baseline correlated with higher relapse rates. Compared with the visit immediately preceding relapse, a significantly increased number of patients with positive anti-Dsg1 (38% vs 31.1%, P = .01), anti-Dsg3 (51.7% vs 41.4%, P = .01) and IgG positivity by DIF (85.7% vs 25%, P < .001) was observed at the time of relapse.
CONCLUSION: Regular monitoring of anti-Dsg 1 and anti-Dsg 3 serum levels and DIF positivity during the course of the disease in remission may predict relapse.
OBJECTIVE: To periodically assess immunological parameters in patients with pemphigus vulgaris and foliaceous in remission to understand immunological events preceding clinical relapse.
METHODS: A total of 105 patients were included. Baseline assessment included direct immunofluorescence (DIF), serum IgG against desmoglein (Dsg) 1, IgG, IgG1, and IgG4 against Dsg 3, IgG against the extracellular domains 1 and 2 of Dsg 3, IgG against muscarinic (M3)-AchR, and peripheral CD19+CD27+ memory B cells/plasma cells, repeated every 3 months for up to 12 months or until clinical relapse. DIF was repeated at month 12 and on relapse.
RESULTS: About 29 of 105 patients (28%) experienced a relapse. Longer duration of clinical remission, presence of pruritus and positive anti-Dsg1 at baseline correlated with higher relapse rates. Compared with the visit immediately preceding relapse, a significantly increased number of patients with positive anti-Dsg1 (38% vs 31.1%, P = .01), anti-Dsg3 (51.7% vs 41.4%, P = .01) and IgG positivity by DIF (85.7% vs 25%, P < .001) was observed at the time of relapse.
CONCLUSION: Regular monitoring of anti-Dsg 1 and anti-Dsg 3 serum levels and DIF positivity during the course of the disease in remission may predict relapse.